

Cure Interviews Brett Pletcher in “Technology Transfer in Biotech and Pharma and the Process of Scaling New Medicines”

Insights

March 11, 2026

Gunderson Dettmer life sciences and public companies advisor Brett Pletcher was featured in Cure’s article, “Technology Transfer in Biotech and Pharma and the Process of Scaling New Medicines,” which discusses how technology transfer works in biotech and pharma, the different types of transfers, and why poor execution can delay commercialization.

Depending on the stage of development when a tech transfer occurs, the process can range from relatively straightforward to highly complex. “If a discovery platform is licensed out, that process is pretty easy,” Brett explained. “The licensor hands over the assays or other discovery technologies, explains how to make and use them, and the parties go on their merry way. The further along the drug gets, the more complicated the tech transfer becomes.”

[Read the full article here.](#)

Related People





Brett Pletcher

ADVISOR

P +1 650 321 2400

Related Services

Life Sciences

Featured Insights

EVENTS

The Nuts and Bolts of an IPO

INSIGHTS

Client Insight: California DFPI Suspends Implementation and Enforcement of Diversity Reporting Law

EVENTS

Post-IPO: Engaging Shareholders with Confidence and Credibility

FIRM NEWS

Associates Recognize Gunderson Dettmer as Top Performer for AI Integration and Associate Experience in Chambers Satisfaction Survey

INSIGHTS

Client Insight: Quarterly Employment Law Update — Winter 2026

CLIENT NEWS

Kaszek Ventures Co-Leads Azos R\$125 Million Series C

CLIENT NEWS

Hims & Hers Announces Agreement to Acquire Eucalyptus

CLIENT NEWS

Gangkhar Announces \$4.25 Million Seed Financing

CLIENT NEWS

Nexthop AI Announces \$500 Million Series B, \$4.2 Billion Valuation

CLIENT NEWS

City Detect Raises \$13 Million Series A

PUBLIC VENTURES

SEC Chair Outlines AI Vision in First Dedicated Address

CLIENT NEWS

Cart.com Announces \$180 Million Strategic Investment